Document is current

Any future updates will be listed below

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

Crossref DOI link: https://doi.org/10.1186/s12885-017-3661-2

Published Online: 2017-10-10

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark